Effects of low dose methotrexate on the bone mineral density of patients with rheumatoid arthritis

Journal of Rheumatology

Volumn 24, Issue 8, 1997, Pages 1489-1494

  Buckley, Lenore M ^a   Leib, Edward S ^b   Cartularo, Kathryn S ^b   Vacek, Pamela M ^c   Cooper, Sheldon M ^b  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Department of Medicine ^*

^c UNIVERSITY OF VERMONT   (United States)

Author keywords

bone mineral density; corticosteroids; methotrexate; osteoporosis

Indexed keywords

METHOTREXATE; PREDNISONE;

ADULT; AGED; ARTICLE; BONE DENSITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OSTEOPOROSIS; PHOTON ABSORPTIOMETRY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS;

ADOLESCENT; ADULT; AGED; ANTI-INFLAMMATORY AGENTS; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BONE DENSITY; CALCIUM; CHOLECALCIFEROL; DENSITOMETRY, X-RAY; DRUG THERAPY, COMBINATION; FEMALE; FEMUR NECK; HUMANS; LUMBAR VERTEBRAE; MALE; METHOTREXATE; MIDDLE AGED; OSTEOPOROSIS; PREDNISONE; PROSPECTIVE STUDIES;

EID: 0030750383     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Kremer JM, Lee JK: A long term prospective study of the use of methotrexate in rheumatoid arthritis: Update after a mean of fifty-three months. Arthritis Rheum 1988;31:577-84.
2. Weinstein A, Marlowe S, Korn J, Karouhar F: Low-dose methotrexate treatment of rheumatoid arthritis: Long term observations. Am J Med 1985;79:331-7.
3. Hughes GR: Methotrexate in rheumatoid arthritis. Ann Rheum Dis 1990;49:275.
4. Waisman HA, Harvey RA: Radiological evidence of growth in children with acute leukemia treated with folic acid antagonist. Radiology 1954;62:61-4.
5. Thomas LB, Forkner CE Jr, Frei E, Besse BE Jr, Stabenau JR: The skeletal lesions of acute leukemia. Cancer 1961;14:608-21.
6. Baty JM, Vogt EC: Bone changes of leukemia in children. Am J Roentgenol 1935;34:310-4.
7. Dennis JM, Mercado R: Scurvy following folic acid antagonist therapy. Radiology 1956;67:412-5.
8. Dresner E: The bone and joint lesions in acute leukemia and their response to folic acid antagonists. Q J Med 1950;19:339-52.
9. Stanisavljevic S, Babcock A: Fractures in children treated with methotrexate for leukemia. Clin Orthop Rel Res 1977;125:139-44.
10. Karpinski F, Martin J: The skeletal lesions of leukemic children treated with aminopterin. J Pediatrics 1950;37:208-23.
11. O'Regan S, Melhorn DK, Newman AJ: Methotrexate-induced bone pain in childhood leukemia. Am J Dis Child 1973;126:489-90.
12. Ragab AH, French RS, Vietti TJ: Osteoporotic fractures secondary to methotrexate therapy of acute leukemia in remission. Cancer 1979;25:580-5.
13. Preston SJ, Diamond T, Scott A, Laurent MR: Methotrexate osteopathy in rheumatic disease. Ann Rheum Dis 1995;52:582-5.
14. Ansell G, Evans S, Jackson CT: Cytotoxic drugs for non-neoplastic disease (letter). BMJ 1983;287:762.
15. May KP, West SG, McDermott MT, Huffer WE: The effect of low-dose methotrexate on bone metabolism and histomorphometry in rats. Arthritis Rheum 1994;37:201-6.
16. Buckley LM, Leib ES, Cartularo KS, Vacek PM, Cooper SM: The effects of low dose corticosteroids on the bone mineral density of patients with rheumatoid arthritis. J Rheumatol 1995;22:1055-9.
17. Hall GM, Spector TD, Griffin AJ, Jawad AS, Hall ML, Doyle DV: The effects of rheumatoid arthritis and steroid therapy on bone density in postmenopausal women. Arthritis Rheum 1993;36:1510-6.
18. Garton MJ, Reid DM: Bone mineral density of the hip and the anteroposterior and lateral dimensions of the spine in men with rheumatoid arthritis: Effects of low-dose corticosteroids. Arthritis Rheum 1993;36:222-8.
19. 3 supplementation prevents bone loss in the spine secondary to low-dose corticosteroids in patients with rheumatoid arthritis. Ann Intern Med 1996;125:961-8.
20. Arnett FC, Edworthy SM, Bloch DA, et al: The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
21. Willet WC, Sampson L, Stampfer MJ, et al: Reproducibility and validity of a semi-quantitative food frequency questionnaire. Am J Epidemiol 1985;122:51-65.
22. Kannel WB, Sorlie P: Some health benefits of physical activity: The Framingham Study. Arch Intern Med 1979;139:857-61.
23. Ramey DR, Reynould JP, Fries JF: The Health Assessment Questionnaire: Status and review. Arthritis Care Res 1992;5:119-29.
24. Steinbrocker O, Traeger CH, Batterman RC: Therapeutic criteria in rheumatoid arthritis. JAMA 1949;140:659-62.
25. Reid IR, Evans MC, Stapleton J: Lateral spine densitometry is a more sensitive indicator of glucocorticoid-induced bone loss. J Bone Miner Res 1992;7:1221-5.
26. Larnach TA, Boyd SJ, Smart RC, Butler SP, Rohl PG, Diamond TH: Reproducibility of lateral spine scans using dual energy x-ray absorptiometry. Calcif Tissue Int 1992;51:225-58.
27. Schwartz AM, Leonidas JC: Methotrexate osteopathy. Skeletal Radiol 1984;11:13-6.
28. Gnudi S, Butturini L, Ripamonti C, Avella M, Bacci G: The effects of methotrexate (MTX) on bone: A densitometric study conducted on 59 patients with MTX administered at different doses. Ital J Orthop Traumatol 1988;14:227-31.
29. Bologna C, Edno L, Anaya JM, et al: Methotrexate concentrations in synovial membrane and trabecular and cortical bone in rheumatoid arthritis patients. Arthritis Rheum 1994;31:1770-3.
30. Katz JN, LeBoff MS, Wade JP, Brown EM, Liang MH: Effect of methotrexate on bone density and calcium homeostasis in rheumatoid arthritis (abstr). Clin Res 1989;37:509A.
31. West SG, Huglen R, Battafarano D, McDermott MT, McBiles M: Low dose weekly methotrexate does not cause osteoporosis in rheumatoid arthritis patients (abstr). Arthritis Rheum 1995;(suppl)38:S312.
32. Laan RF, van Riel PL, van de Putte LB, van Erning LJ, van't Hoff MA, Lemmens JA: Low dose prednisone induces rapid reversible axial bone loss in patients with rheumatoid arthritis: A randomized, controlled study. Ann Intern Med 1993;119:963-8.
33. Freeman-Narrod M, Narrod SA: Chronic toxicity of methotrexate in mice. J Natl Cancer Inst 1977;58:735-41.
34. 3. J Bone Miner Res 1995;10:874-80.
35. Segal R, Mozes E, Yaron M, Tartakovsky B: The effects of methotrexate on the production and activity of interleukin-1. Arthritis Rheum 1989;32:370-7.
36. Thomas R, Carroll GJ: Reduction of leukocyte and interleukin-1ß concentrations in the synovial fluid of rheumatoid arthritis patients treated with methotrexate. Arthritis Rheum 1993;36:1244-52.
37. Miller LC, Orencole SF: Interleukin-1ß is structurally related to dihydrofolate reductase: Effects of methotrexate on IL-1 (abstr). Lymphokine Res 1988;7:149.
38. Kimble RB, Kitazawa R, Vannice JL, Pacifici R: Persistent bone-sparing effect of interleukin-1 receptor antagonist: A hypothesis on the role of IL-1 in ovariectomy induced bone loss. Calcif Tissue Int 1994;55:260-5.
39. Chyun YS, Kream BE, Raisz LG: Cortisol decreases bone formation by inhibiting periosteal cell proliferation. Endocrinology 1984;114:447-80.
40. Lukert BP, Johnson BE, Robinson RG: Estrogen and progesterone replacement therapy reduces glucocorticoid-induced bone loss. J Bone Miner Res 1992;7:1063-9.
41. Hall GM, Daniels M, Doyle DV, Spector TD: Effect of hormone replacement therapy on bone mass in rheumatoid arthritis patients treated with and without steroids. Arthritis Rheum 1994;37:1499-505.